Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study
Authors:
Open Access
- 7 February 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (4) , ziae016
Abstract
Background: Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP). Methods: We conducted a 6-month prospective observational study on postmenopausal women with severe OP receiving treatment with romosozumab either alone (in patients naïve to treatment) or in combination with ongoing long-term denosumab (>2 years) or continuing ongoing denosumab alone (>2 years). We collected serum samples for bone turnover markers, bone modulators, and calcium phosphate metabolism at baseline, month 3 and month 6. BMD was assessed at baseline and after 6 months. Results: Fifty-two postmenopausal women with OP were included in the study. Nineteen received romosozumab alone, 11 received romosozumab combined to ongoing denosumab, and 22 continued denosumab alone. BMD increased significantly at all sites at 6 months of follow-up in the romosozumab alone group (femoral neck +8.1%, total hip +6.8%, and lumbar spine +7.9%). In contrast, BMD increased significantly only at lumbar spine in the combination group (+7.2%) and in the denosumab group (+1.5%). P1nP increased significantly in romosozumab groups at month 3 (+70.4% in romosozumab alone group and +99.1% in combination group). Sclerostin levels increased steeply in both romosozumab groups, and Dkk1 did not change. Conclusion: Romosozumab added to ongoing denosumab resulted in an increase in P1nP and lumbar spine BMD, but not in femoral neck BMD. For patients on denosumab, using romosozumab as an additional treatment appeared to be useful in terms of bone formation markers and spine BMD vs denosumab alone. Further randomized controlled trials, possibly powered to fracture outcomes, are needed to confirm our results.Keywords
This publication has 29 references indexed in Scilit:
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2016
- Teriparatide and denosumab combination therapy and skeletal metabolismOsteoporosis International, 2016
- A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repairNature Communications, 2016
- Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis StudyThe Journal of Clinical Endocrinology & Metabolism, 2016
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trialThe Lancet, 2015
- Assessment of Fracture Risk in A Population of Postmenopausal Italian Women: A Comparison of Two Different ToolsCalcified Tissue International, 2015
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled studyThe Journal of Clinical Pharmacology, 2013
- Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumabJournal of Bone and Mineral Research, 2012
- Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostinBone, 2012
- Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description.2010